Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program
Bibliographic record
Abstract
INTRODUCTION: Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved in several countries to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Limited data are available on tildrakizumab treatment patterns in clinical practice. The Canadian tildrakizumab patient support program (PSP), which provides personalized reimbursement, financial aid, and injection training support for disease management, was used in this study to evaluate real-world persistence and adherence to tildrakizumab. METHODS: This retrospective, observational study used data collected in the Canadian tildrakizumab PSP database between August 4, 2021, and August 1, 2023. Adult (≥18 years) patients with moderate-to-severe plaque psoriasis who enrolled in the PSP and received ≥6 months of treatment with tildrakizumab before August 1, 2023, were included. Data up to Week 52 following treatment initiation were analyzed. Persistence was defined as the number of days until treatment discontinuation. Adherence was measured as the proportion of days covered (PDC) from treatment initiation to treatment discontinuation or study cutoff, with PDC ≥80% indicating high adherence. RESULTS: The study included 813 patients with a mean ± standard deviation (SD) age of 49.6 ± 15.9 years; 55.0% (447/813) were male, and 92.7% (754/813) were biologic-naïve when initiating tildrakizumab. Patients received tildrakizumab treatment for a mean ± SD of 329.6 ± 55.0 days. After 1 year, 88.0% of patients were persistent on treatment. Adherence was also high, with mean ± SD PDC being 97.5% ± 8.9% and 93.5% of patients having PDC ≥80%. Eighty-five patients discontinued treatment, primarily because of switching to other therapies. Common adverse outcomes included treatment misuse (18.9%), disease flare (8.2%), and treatment discontinuation (7.4%). CONCLUSION: Persistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.003 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.002 | 0.006 |
| Science and technology studies | 0.001 | 0.000 |
| Scholarly communication | 0.001 | 0.000 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".